238 related articles for article (PubMed ID: 31619207)
1. Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study.
Rujkijyanont P; Photia A; Traivaree C; Monsereenusorn C; Anurathapan U; Seksarn P; Sosothikul D; Techavichit P; Sanpakit K; Phuakpet K; Wiangnon S; Chotsampancharoen T; Chainansamit SO; Kanjanapongkul S; Meekaewkunchorn A; Hongeng S
BMC Cancer; 2019 Oct; 19(1):961. PubMed ID: 31619207
[TBL] [Abstract][Full Text] [Related]
2. Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).
Mora J; Cruz O; Lavarino C; Rios J; Vancells M; Parareda A; Salvador H; Suñol M; Carrasco R; Guillen A; Mañé S; de Torres C
Clin Transl Oncol; 2015 Jul; 17(7):521-9. PubMed ID: 25596034
[TBL] [Abstract][Full Text] [Related]
3. Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.
De Ioris MA; Castellano A; Ilari I; Garganese MC; Natali G; Inserra A; De Vito R; Ravà L; De Pasquale MD; Locatelli F; Donfrancesco A; Jenkner A
Eur J Cancer; 2011 Mar; 47(4):572-8. PubMed ID: 21112775
[TBL] [Abstract][Full Text] [Related]
4. Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age.
Donfrancesco A; Jenkner A; Castellano A; Ilari I; Milano GM; De Sio L; Cozza R; Fidani P; Deb G; De Laurentis C; Inserra A; Dominici C
Acta Paediatr Suppl; 2004 May; 93(445):6-11. PubMed ID: 15176712
[TBL] [Abstract][Full Text] [Related]
5. Rapid COJEC versus standard induction therapies for high-risk neuroblastoma.
Peinemann F; Tushabe DA; van Dalen EC; Berthold F
Cochrane Database Syst Rev; 2015 May; 2015(5):CD010774. PubMed ID: 25989478
[TBL] [Abstract][Full Text] [Related]
6. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.
Kaneko M; Tsuchida Y; Mugishima H; Ohnuma N; Yamamoto K; Kawa K; Iwafuchi M; Sawada T; Suita S
J Pediatr Hematol Oncol; 2002 Nov; 24(8):613-21. PubMed ID: 12439032
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of efficacy of treatment for 30 children with neuroblastoma].
Sun XF; Liu DG; Su YS; Lin TY; Chen XQ; He YJ
Ai Zheng; 2003 Dec; 22(12):1343-5. PubMed ID: 14693065
[TBL] [Abstract][Full Text] [Related]
8. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study.
Park JR; Scott JR; Stewart CF; London WB; Naranjo A; Santana VM; Shaw PJ; Cohn SL; Matthay KK
J Clin Oncol; 2011 Nov; 29(33):4351-7. PubMed ID: 22010014
[TBL] [Abstract][Full Text] [Related]
9. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial.
Simon T; Längler A; Harnischmacher U; Frühwald MC; Jorch N; Claviez A; Berthold F; Hero B
J Cancer Res Clin Oncol; 2007 Sep; 133(9):653-61. PubMed ID: 17479288
[TBL] [Abstract][Full Text] [Related]
10. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.
Kushner BH; Kramer K; LaQuaglia MP; Modak S; Yataghene K; Cheung NK
J Clin Oncol; 2004 Dec; 22(24):4888-92. PubMed ID: 15611504
[TBL] [Abstract][Full Text] [Related]
11. Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study.
Amoroso L; Erminio G; Makin G; Pearson ADJ; Brock P; Valteau-Couanet D; Castel V; Pasquet M; Laureys G; Thomas C; Luksch R; Ladenstein R; Haupt R; Garaventa A;
Cancer Res Treat; 2018 Jan; 50(1):148-155. PubMed ID: 28324923
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Neuroblastoma with a Novel Delayed Intensification Chemotherapy.
Zhang YT; Chang J; Xu HM; Li YN; Zhong XD; Liu ZL
Indian J Pediatr; 2019 Feb; 86(2):126-131. PubMed ID: 30076520
[TBL] [Abstract][Full Text] [Related]
13. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
14. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol.
Valteau-Couanet D; Michon J; Boneu A; Rodary C; Perel Y; Bergeron C; Rubie H; Coze C; Plantaz D; Bernard F; Chastagner P; Bouzy J; Hartmann O
J Clin Oncol; 2005 Jan; 23(3):532-40. PubMed ID: 15659499
[TBL] [Abstract][Full Text] [Related]
15. Dose-intensive use of cyclophosphamide in ablation of neuroblastoma.
Kushner BH; O'Reilly RJ; LaQuaglia M; Cheung NK
Cancer; 1990 Sep; 66(6):1095-100. PubMed ID: 2400963
[TBL] [Abstract][Full Text] [Related]
16. Improved Outcomes with Induction Chemotherapy Combined with Arsenic Trioxide in Stage 4 Neuroblastoma: A Case Series.
Li Y; Feng C; Chen Y; Huang K; Li C; Xiong X; Li P; Zhou D; Peng X; Weng W; Deng X; Wu Y; Fang J
Technol Cancer Res Treat; 2021; 20():15330338211041454. PubMed ID: 34569870
[No Abstract] [Full Text] [Related]
17. NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology.
Coze C; Hartmann O; Michon J; Frappaz D; Dusol F; Rubie H; Plouvier E; Leverger G; Bordigoni P; Béhar C; Beck D; Mechinaud F; Bergeron C; Plantaz D; Otten J; Zucker JM; Philip T; Bernard JL
J Clin Oncol; 1997 Dec; 15(12):3433-40. PubMed ID: 9396394
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group.
Zage PE; Kletzel M; Murray K; Marcus R; Castleberry R; Zhang Y; London WB; Kretschmar C;
Pediatr Blood Cancer; 2008 Dec; 51(6):747-53. PubMed ID: 18704922
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma.
Garaventa A; Luksch R; Biasotti S; Severi G; Pizzitola MR; Viscardi E; Prete A; Mastrangelo S; Podda M; Haupt R; De Bernardi B
Cancer; 2003 Dec; 98(11):2488-94. PubMed ID: 14635085
[TBL] [Abstract][Full Text] [Related]
20. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.
Kushner BH; Cheung IY; Kramer K; Modak S; Cheung NK
Pediatr Blood Cancer; 2007 Apr; 48(4):430-4. PubMed ID: 16421906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
